Patricio Canales-Salgado

Patricio Canales-Salgado

Auto-generated profile, based on publicly available information

Patricio Canales-Salgado

Universidad de Santiago de Chile, Faculty of Medical Sciences, School of Kinesiology, Santiago, Chile

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 July 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
NMNicole Morales-Camilo
Nicole Morales-Camilo
JLJingzhun Liu
Jingzhun Liu
MRManuel J. Ramírez
Manuel J. Ramírez
PCPatricio Canales-Salgado
Patricio Canales-Salgado
JAJuan José Alegría
Juan José Alegría
CBCristina Bertocchi
Cristina Bertocchi
Force transmission through adherens junctions (AJs) is crucial for multicellular organization, wound healing and tissue regeneration. Recent studies shed light on the molecular mechanisms of mechanotransduction at the AJs. However, the canonical model fails to explain force transmission when essential proteins of the mechanotransduction module are mutated or missing. Here, we demonstrate that, in absence of α-catenin, β-catenin can directly and functionally interact with vinculin in its open conformation, bearing physiological forces. Furthermore, we found that β-catenin can prevent vinculin autoinhibition in the presence of α-catenin by occupying vinculin´s head-tail interaction site, thus preserving force transmission capability. Taken together, our findings suggest a multi-step force transmission process at AJs, where α-catenin and β-catenin can alternatively and cooperatively interact with vinculin. This can explain the graded responses needed to maintain tissue mechanical homeostasis and, importantly, unveils a force-bearing mechanism involving β-catenin and extended vinculin that can potentially explain the underlying process enabling collective invasion of metastatic cells lacking α-catenin.

8 October 2026 in Current Respiratory Medicine Reviews
Verified
Journal Article
Closed access
PDF file
FPFrancisco Pérez-Lefimil
Francisco Pérez-Lefimil
PCPatricio Canales-Salgado
Patricio Canales-Salgado
PFPiery Freyhofer-Rivera
Piery Freyhofer-Rivera
MGManuel Gálvez-Reyes
Manuel Gálvez-Reyes
RVRoberto Vera-Salazar
Roberto Vera-Salazar
JMJosé Luis Márquez
José Luis Márquez
Introduction/Objective: Non-coding RNA (ncRNA) dysregulation has been widely investigated in Chronic Obstructive Pulmonary Disease (COPD), but interpretation of human evidence is limited by heterogeneity in smoking status, biological source, and analytical methods. This systematic review aimed to synthesize comparable evidence using explicit eligibility criteria. Methods: Scopus, Web of Science, PubMed, and SciELO were searched through April 2025. Eligible studies were original human case-control studies comparing adults with COPD with healthy nonsmoker controls with normal lung function and reporting RT-qPCR-validated ncRNA expression with quantitative fold-change data. Two reviewers independently screened studies, extracted data, and assessed methodological quality using the Newcastle-Ottawa Scale. Results: Of 1,155 records identified, 8 studies met the eligibility criteria; although the search encompassed ncRNAs broadly, all eligible studies investigated mature miRNAs. Thirteen miRNAs were significantly dysregulated in bronchoalveolar lavage fluid, alveolar macrophages, peripheral blood mononuclear cells, plasma, and serum. Seven were upregulated and six were downregulated, with log2 fold-change values ranging from -2.15 to +2.85. Methodological quality ranged from 5 to 7. Discussion: The available human evidence indicates that miRNA dysregulation is detectable in both pulmonary and circulating compartments in COPD. However, the small number of eligible studies and the remaining biological and methodological heterogeneity limit direct cross-study comparability and constrain the current strength of the biomarker evidence. Conclusion: Only a small subset of miRNAs currently meets sufficient methodological and experimental standards to support cautious consideration as exploratory biomarker candidates in COPD. PROSPERO registration: CRD420251042988.